Chat IA
Loading data for DERM — first visit, this takes a few seconds.

Journey Medical Corporation

DERM · NasdaqCM · USD

7.23 +0.14 (1.97%)

À la clôture : Sep 11, 2026, 8:00 PM

7.23 +0.00%

Après-Bourse: 4:10 PM

Volume
168K

Journey Medical Corporation (DERM) : cours, analyse et données

Valeur intrinsèque

Chargement de la valeur intrinsèque…

Prévisions des analystes

Prévisions boursières →

Prévisions des analystes indisponibles

Objectif à 12 mois · n/a analystes

Consensus des analystes : n/a

Intervalle:1D
Chargement des bougies et signaux…

Performance financière

Voir les finances →

Chargement...

Derniers résultats

SignaléÉcart estiméChangement d’une année sur l’autre
Chiffre d’affaires$15.96Mn/a+21.48%
EPS-$0.01+$0.01+93.75%

Prochains résultats

pendant les heures de marché.

Estimation · Passer à l’offre supérieure →

Voir les résultats détaillés →

Métriques

Cours acheteur
5.17
Résultat net (ttm)
-6.1M
1.10
-0.22
n/a
-120.5
P/B (ttm)
6.23
P/S (ttm)
2.99
Date des résultats
Nov 11, 2026
Cours vendeur
9.24
Volume
167,997
Volume moy. (20D)
242,456
Ouverture
7.18
Clôture précédente
7.09
Fourchette du jour
7.06 - 7.41
Intervalle de 52 semaines
4.31 - 9.55
Date ex-dividende
n/a

À propos de Journey Medical Corporation

Voir le profil →
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Drug Manufacturers - Specialty & Generic · Healthcare

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

Secteur Healthcare
Date d’introduction Nov 12, 2021
Employés 58
Bourse NasdaqCM
Symbole boursier DERM